S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
Why Your IRA Could Crash on June 16th (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Laser breakthrough could send stock soaring 2,467% (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
66,000% upside on tiny biotech? (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
Why Your IRA Could Crash on June 16th (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Laser breakthrough could send stock soaring 2,467% (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
66,000% upside on tiny biotech? (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
Why Your IRA Could Crash on June 16th (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Laser breakthrough could send stock soaring 2,467% (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
66,000% upside on tiny biotech? (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
Why Your IRA Could Crash on June 16th (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Laser breakthrough could send stock soaring 2,467% (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
66,000% upside on tiny biotech? (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
NASDAQ:BLU

BELLUS Health (BLU) Competitors

$14.61
0.00 (0.00%)
(As of 06/1/2023 ET)
Compare
Today's Range
$14.57
$14.62
50-Day Range
$6.46
$14.61
52-Week Range
$6.38
$14.65
Volume
1.18 million shs
Average Volume
3.05 million shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

BLU vs. SUPN, PCRX, ABCL, VTYX, CVAC, GERN, SLRN, FGEN, RCKT, and IRWD

Should you be buying BELLUS Health stock or one of its competitors? The main competitors of BELLUS Health include Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), AbCellera Biologics (ABCL), Ventyx Biosciences (VTYX), CureVac (CVAC), Geron (GERN), Acelyrin (SLRN), FibroGen (FGEN), Rocket Pharmaceuticals (RCKT), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.

BELLUS Health vs.

Supernus Pharmaceuticals (NASDAQ:SUPN) and BELLUS Health (NASDAQ:BLU) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.

99.8% of Supernus Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.1% of BELLUS Health shares are owned by institutional investors. 8.0% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 24.2% of BELLUS Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Supernus Pharmaceuticals has a net margin of 7.79% compared to BELLUS Health's net margin of -578,586.63%. Supernus Pharmaceuticals' return on equity of 5.96% beat BELLUS Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals 7.79% 5.96% 3.02%
BELLUS Health -578,586.63% -24.27% -23.14%

Supernus Pharmaceuticals has higher revenue and earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$667.24 million2.69$60.71 million$0.8937.03
BELLUS Health$20 thousand92,627.40-$76.08 million-$0.72-20.29

In the previous week, Supernus Pharmaceuticals had 3 more articles in the media than BELLUS Health. MarketBeat recorded 3 mentions for Supernus Pharmaceuticals and 0 mentions for BELLUS Health. Supernus Pharmaceuticals' average media sentiment score of 1.41 beat BELLUS Health's score of 0.00 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Supernus Pharmaceuticals Positive
BELLUS Health Neutral

Supernus Pharmaceuticals currently has a consensus target price of $46.00, suggesting a potential upside of 39.56%. BELLUS Health has a consensus target price of $16.50, suggesting a potential upside of 12.94%. Given Supernus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Supernus Pharmaceuticals is more favorable than BELLUS Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
BELLUS Health
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

Supernus Pharmaceuticals received 435 more outperform votes than BELLUS Health when rated by MarketBeat users. Likewise, 73.65% of users gave Supernus Pharmaceuticals an outperform vote while only 65.91% of users gave BELLUS Health an outperform vote.

CompanyUnderperformOutperform
Supernus PharmaceuticalsOutperform Votes
464
73.65%
Underperform Votes
166
26.35%
BELLUS HealthOutperform Votes
29
65.91%
Underperform Votes
15
34.09%

Supernus Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, BELLUS Health has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500.

Summary

Supernus Pharmaceuticals beats BELLUS Health on 15 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLU vs. The Competition

MetricBELLUS HealthPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.85B$5.82B$4.54B$5.82B
Dividend YieldN/A2.74%2.42%6.15%
P/E Ratio-20.298.87137.9814.18
Price / Sales92,627.40327.543,638.9295.76
Price / CashN/A20.1191.04108.31
Price / Book5.025.435.157.27
Net Income-$76.08M$190.11M$117.90M$175.81M
7 Day Performance0.27%8.11%3.20%2.65%
1 Month Performance0.69%7.78%3.13%3.15%
1 Year Performance89.99%24.03%23.05%1.84%

BELLUS Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SUPN
Supernus Pharmaceuticals
2.6358 of 5 stars
$33.26
-1.1%
$46.00
+38.3%
+17.8%$1.81B$667.24M37.37575Positive News
PCRX
Pacira BioSciences
2.3048 of 5 stars
$39.26
-0.5%
$62.73
+59.8%
-40.0%$1.81B$666.82M-145.41697Analyst Revision
Positive News
ABCL
AbCellera Biologics
2.0715 of 5 stars
$6.95
+2.2%
$25.57
+267.9%
-12.9%$1.96B$181.04M-38.61386Positive News
VTYX
Ventyx Biosciences
1.9764 of 5 stars
$33.88
-1.7%
$55.40
+63.5%
+98.7%$1.98BN/A-14.8627Insider Selling
Positive News
CVAC
CureVac
1.9023 of 5 stars
$8.87
-3.1%
$21.00
+136.8%
-51.0%$1.99B$72.33M0.001,049
GERN
Geron
2.0198 of 5 stars
$3.32
+2.2%
$5.00
+50.6%
+154.1%$1.69B$600,000.00-9.7669
SLRN
Acelyrin
0 of 5 stars
$18.17
-5.7%
N/AN/A$1.68BN/A0.00N/AAnalyst Report
Gap Up
FGEN
FibroGen
2.0736 of 5 stars
$17.11
+2.5%
$23.40
+36.8%
+80.2%$1.67B$140.73M-5.23566Analyst Upgrade
RCKT
Rocket Pharmaceuticals
2.385 of 5 stars
$20.65
-2.6%
$51.09
+147.4%
+86.9%$1.66BN/A-6.16151
IRWD
Ironwood Pharmaceuticals
2.1456 of 5 stars
$10.75
-0.6%
$15.67
+45.7%
-3.0%$1.66B$410.60M10.64219Analyst Upgrade
Insider Selling

Related Companies and Tools

This page (NASDAQ:BLU) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -